<DOC>
	<DOCNO>NCT00124215</DOCNO>
	<brief_summary>The GI-5005 therapeutic vaccine placebo inject skin hepatitis C virus ( HCV ) subject . Patients monitor safety , immune response therapeutic benefit relate injection .</brief_summary>
	<brief_title>Safety Efficacy Therapeutic Vaccine GI-5005 Versus Placebo Treatment Chronic Hepatitis C Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Patients chronic hepatitis C virus infection include treatment naive subject well subject partial responder relapsers prior interferon therapy &gt; 18 year age Negative skin test hypersensitivity saccharomyces cerevisiae . Nonresponders previous interferon treatment Cirrhosis HCV treatment within 3 month Hepatitis B infection HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Hepatitis</keyword>
	<keyword>HCV</keyword>
	<keyword>vaccine</keyword>
	<keyword>Hepatitis C Infection</keyword>
</DOC>